Coloplast (COLO) CMD 2025 summary

Strategic direction and organizational structure

• Launched the five-year Impact4 strategy, aiming to double the customer base to 4 million, with a focus on customer-centricity, innovation, efficiency, technology, and leadership culture.

• Reorganized into two business units: Chronic Care (covering Ostomy, Continence, Voice & Respiratory Care) and Acute Care (including Wound & Tissue Repair and Interventional Urology), supported by a new Executive Leadership Team.

• Market fundamentals remain stable, with growth driven by demographics and emerging markets, but China has become more challenging, prompting cost base adjustments.

• AI and technology are central, with significant investments in digital infrastructure and a dedicated five-year program to enhance customer service and operational efficiency.

• Sustainability is a key focus, targeting 90% reduction in Scope 1+2 emissions and 10% per product by 2029/30, net zero by 2045, and 15-20% less materials in products and packaging.

Financial guidance and performance targets

• Organic revenue growth target is 7-8% CAGR through FY 2029/30, with EBIT growth at or above revenue growth and ROIC expected to exceed 20% by 2030.

• FY 2024/25 guidance: around 7% organic revenue growth and 27-28% EBIT margin.

• Free cash flow to sales targeted above 20%, with CapEx-to-sales ratio to decline to 4-5% as major facility investments wind down.

• Dividend payout ratio to remain at 60-80% of net profit, with share buybacks expected to resume within two to three years.

• NWC-to-sales ratio to improve to ~24% and net debt/EBITDA to decrease to ~1.5x by FY 2029/30.

Business unit and product innovation

• Chronic Care unit leverages strong market leadership, comprehensive product portfolio, and new reimbursement opportunities to drive above-market growth.

• Wound & Tissue Repair, including Kerecis, targets double-digit growth and improved profitability, with Kerecis contributing the majority.

• Interventional Urology aims for mid- to high-single-digit growth, with new product launches like Intibia and profitability improvement.

• Multiple product launches are planned, especially in SenSura Mio, Luja, and leveraging fish-skin technology, to expand the innovation pipeline and set new standards of care.

• Dynamic resource allocation prioritizes high-potential areas, including US Chronic Care, Kerecis, and Intibia commercialization.